Perspective Therapeutics, Inc.
CATX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $209 | $290 | $342 | $0 |
| % Growth | -27.9% | -15.2% | – | – |
| Cost of Goods Sold | $775 | $733 | $732 | $0 |
| Gross Profit | -$566 | -$443 | -$390 | $0 |
| % Margin | -270.8% | -152.8% | -114% | – |
| R&D Expenses | $20,339 | $12,174 | $14,332 | $12,883 |
| G&A Expenses | $7,731 | $7,709 | $7,842 | $8,246 |
| SG&A Expenses | $7,731 | $7,709 | $7,842 | $8,246 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$775 | $3,713 | -$342 | $23,855 |
| Operating Expenses | $27,295 | $23,596 | $21,832 | $46,438 |
| Operating Income | -$27,861 | -$24,039 | -$21,832 | -$44,984 |
| % Margin | -13,330.6% | -8,289.3% | -6,383.6% | – |
| Other Income/Exp. Net | $1,892 | $2,040 | $3,655 | $2,718 |
| Pre-Tax Income | -$25,969 | -$21,999 | -$18,177 | -$42,266 |
| Tax Expense | $0 | $0 | $0 | -$2,097 |
| Net Income | -$25,969 | -$21,485 | -$18,177 | -$40,169 |
| % Margin | -12,425.4% | -7,408.6% | -5,314.9% | – |
| EPS | -0.35 | -0.3 | -0.25 | -0.57 |
| % Growth | -16.7% | -20% | 56.1% | – |
| EPS Diluted | -0.35 | -0.3 | -0.25 | -0.57 |
| Weighted Avg Shares Out | 74,296 | 70,671 | 72,357 | 70,629 |
| Weighted Avg Shares Out Dil | 74,296 | 70,671 | 72,357 | 70,629 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,957 | $2,159 | $2,384 | $2,647 |
| Interest Expense | $65 | $119 | $128 | -$73 |
| Depreciation & Amortization | $775 | $733 | $732 | $721 |
| EBITDA | -$25,129 | -$21,147 | -$17,317 | -$41,618 |
| % Margin | -12,023.4% | -7,292.1% | -5,063.5% | – |